Sustained CD4+ T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide

OncoImmunology

Volumn 3, Issue 1, 2014, Pages

  Ellsworth, Susannah ^a   Balmanoukian, Ani ^a   Kos, Ferdynand ^b   Nirschl, Christopher J ^a   Nirschl, Thomas R ^a   Grossman, Stuart A ^a   Luznik, Leo ^a   Drake, Charles G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Glioblastoma; IL 7; Immunotherapy; Lymphocytes; Radiation therapy; Radiotherapy

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 7; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER GRADING; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CYTOKINE RESPONSE; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOASSAY; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; MONONUCLEAR CELL; MULTIPLEX BEAD BASED IMMUNOASSAY; NATURAL KILLER CELL; PATHOPHYSIOLOGY; PHENOTYPE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RADIATION DOSE FRACTIONATION; REGULATORY T LYMPHOCYTE;

EID: 84899118144     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27357     Document Type: Article

References (42)

1. Reardon DA, Rich JN, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 2006; 24:1253-65; PMID:16525180; http://dx.doi.org/10.1200/JCO.2005.04.5302.
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10:459-66; PMID:19269895; http://dx.doi. org/10.1016/S1470-2045(09)70025-7.
3. Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, Desideri S, Piantadosi S; NABTT CNS Consortium. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res 2011; 17:5473-80; PMID:21737504; http://dx.doi.org/10.1158/1078-0432.CCR-11-0774.
4. Meyer KK. Radiation-induced lymphocyte-immune deficiency. A factor in the increased visceral metastases and decreased hormonal responsiveness of breast cancer. Arch Surg 1970; 101:114-21; PMID:5451189; http://dx.doi.org/10.1001/archsurg.1970.01340260018003.
5. Hughes MA, Parisi M, Grossman S, Kleinberg L. Primary brain tumors treated with steroids and radiotherapy: low CD4 counts and risk of infection. Int J Radiat Oncol Biol Phys 2005; 62:1423-6; PMID:16029802; http://dx.doi.org/10.1016/j. ijrobp.2004.12.085.
6. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011; 480:480-9; PMID:22193102; http://dx.doi.org/10.1038/nature10673.
7. Fry TJ, Mackall CL. Interleukin-7: from bench to clinic. Blood 2002; 99:3892-904; PMID:12010786; http://dx.doi.org/10.1182/blood.V99.11.3892.
8. Sportès C, Babb RR, Krumlauf MC, Hakim FT, Steinberg SM, Chow CK, Brown MR, Fleisher TA, Noel P, Maric I, et al. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res 2010; 16:727-35; PMID:20068111; http://dx.doi. org/10.1158/1078-0432.CCR-09-1303.
9. Rosenberg SA, Sportès C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, Stetler-Stevenson M, Morton KE, Mavroukakis SA, Morre M, et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 2006; 29:313-9; PMID:16699374; http://dx.doi.org/10.1097/01. cji.0000210386.55951.c2.
10. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood 2001; 97:14-32; PMID:11133738; http://dx.doi.org/10.1182/blood.V97.1.14.
11. Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998; 10:588-94; PMID:9794842; http://dx.doi.org/10.1016/S0952-7915(98)80228-8.
12. Curiel TJ. Regulatory T cells and treatment of cancer. Curr Opin Immunol 2008; 20:241-6; PMID:18508251; http://dx.doi.org/10.1016/j. coi.2008.04.008.
13. Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008; 118:1991-2001; PMID:18523649; http://dx.doi.org/10.1172/JCI35180.
14. Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011; 11:330-42; PMID:21508983; http://dx.doi.org/10.1038/nri2970.
15. Darcissac EC, Vidal V, De La Tribonniere X, Mouton Y, Bahr GM. Variations in serum IL-7 and 90K/Mac-2 binding protein (Mac-2 BP) levels analysed in cohorts of HIV-1 patients and correlated with clinical changes following antiretroviral therapy. Clin Exp Immunol 2001; 126:287-94; PMID:11703373; http://dx.doi.org/10.1046/j.1365-2249.2001.01670.x.
16. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26:5233-9; PMID:18809613; http://dx.doi.org/10.1200/JCO.2008.16.5449.
17. Bolotin E, Annett G, Parkman R, Weinberg K. Serum levels of IL-7 in bone marrow transplant recipients: relationship to clinical characteristics and lymphocyte count. Bone Marrow Transplant 1999; 23:783-8; PMID:10231140; http://dx.doi.org/10.1038/sj.bmt.1701655.
18. Yovino S, Grossman SA. Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas. CNS Oncol 2012; 1:149-54; PMID:23828734; http://dx.doi.org/10.2217/cns.12.14.
19. De Ruysscher D, Waer M, Vandeputte M, Aerts R, Vantongelen K, van der Schueren E. Changes of lymphocyte subsets after local irradiation for early stage breast cancer and seminoma testis: long-term increase of activated (HLA-DR+) T cells and decrease of "naive" (CD4-CD45R) T lymphocytes. Eur J Cancer 1992; 28A:1729-34; PMID:1389495; http://dx.doi. org/10.1016/0959-8049(92)90079-H.
20. Rohowsky-Kochan C, Molinaro D, Devereux C, Troiano R, Bansil S, Zito G, Wolansky L, Jotkowitz A, Denny T, Oleske J, et al. The effect of total lymphoid irradiation and low-dose steroids on T lymphocyte populations in multiple sclerosis: correlation with clinical and MRI status. J Neurol Sci 1997; 152:182-92; PMID:9415540; http://dx.doi. org/10.1016/S0022-510X(97)00156-1.
21. Tanay A, Field EH, Hoppe RT, Strober S. Long-term followup of rheumatoid arthritis patients treated with total lymphoid irradiation. Arthritis Rheum 1987; 30:1-10; PMID:2949753; http://dx.doi. org/10.1002/art.1780300101.
22. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. ht tp://a id s info.nih.gov/guidel ine s/html/1/adult-and-adolescent-arv-guidelines/0.
23. Nakamura N, Kusunoki Y, Akiyama M. Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay. Radiat Res 1990; 123:224-7; PMID:2117766; http://dx.doi.org/10.2307/3577549.
24. Gea-Banacloche JC. Rituximab-associated infections. Semin Hematol 2010; 47:187-98; PMID:20350666; http://dx.doi.org/10.1053/j. seminhematol.2010.01.002.
25. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-33; PMID:9704735.
26. Mahindra AK, Grossman SA. Pneumocystis carinii pneumonia in HIV negative patients with primary brain tumors. J Neurooncol 2003; 63:263-70; PMID:12892232; http://dx.doi. org/10.1023/A:1024217527650.
27. Schiff D. Pneumocystis pneumonia in brain tumor patients: risk factors and clinical features. J Neurooncol 1996; 27:235-40; PMID:8847557; http://dx.doi.org/10.1007/BF00165480.
28. Balmanoukian A, Ye X, Herman J, Laheru D, Grossman SA. The association between treatmentrelated lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas. Cancer Invest 2012; 30:571-6; PMID:22812722; http://dx.doi.org/10.3109/07357 907.2012.700987.
29. Wild AT, Ye X, Ellsworth SG, Smith JA, Narang AK, Garg T, Campian J, Laheru DA, Zheng L, Wolfgang CL, et al. The association between chemoradiation-related lymphopenia and clinical outcomes in patients with locally advanced pancreatic adenocarcinoma. Am J Clin Oncol 2013; Forthcoming; PMID:23648440; http://dx.doi.org/10.1097/COC.0b013e3182940ff9.
30. Campian JL, Ye X, Brock M, Grossman SA. Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer. Cancer Invest 2013; 31:183-8; PMID:23432821; http://dx.doi.org/10.31 09/07357907.2013.767342.
31. Puel A, Leonard WJ. Mutations in the gene for the IL-7 receptor result in T(-)B(+)NK(+) severe combined immunodeficiency disease. Curr Opin Immunol 2000; 12:468-73; PMID:10899029; http://dx.doi.org/10.1016/S0952-7915(00)00122-9.
32. Roifman CM, Zhang J, Chitayat D, Sharfe N. A partial deficiency of interleukin-7R alpha is sufficient to abrogate T-cell development and cause severe combined immunodeficiency. Blood 2000; 96:2803-7; PMID:11023514.
33. Hakim FT, Gress RE. Reconstitution of the lymphocyte compartment after lymphocyte depletion: a key issue in clinical immunology. Eur J Immunol 2005; 35:3099-102; PMID:16231288; http://dx.doi. org/10.1002/eji.200535385.
34. Napolitano LA, Burt TD, Bacchetti P, Barrón Y, French AL, Kovacs A, Anastos K, Young M, McCune JM, Greenblatt RM. Increased circulating interleukin-7 levels in HIV-1-infected women. J Acquir Immune Defic Syndr 2005; 40:581-4; PMID:16284535; http://dx.doi.org/10.1097/01. qai.0000187442.53708.b4.
35. Sereti I, Dunham RM, Spritzler J, Aga E, Proschan MA, Medvik K, Battaglia CA, Landay AL, Pahwa S, Fischl MA, et al.; ACTG 5214 Study Team. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009; 113:6304-14; PMID:19380868; http://dx.doi.org/10.1182/blood-2008-10-186601.
36. Budagian V, Bulanova E, Paus R, Bulfone-Paus S. IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev 2006; 17:259-80; PMID:16815076; http://dx.doi. org/10.1016/j.cytogfr.2006.05.001.
37. Mitchell DA, Cui X, Schmittling RJ, Sanchez-Perez L, Snyder DJ, Congdon KL, Archer GE, Desjardins A, Friedman AH, Friedman HS, et al. Monoclonal antibody blockade of IL-2 receptor a during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood 2011; 118:3003-12; PMID:21768296; http://dx.doi.org/10.1182/blood-2011-02-334565.
38. Miller CN, Hartigan-O'Connor DJ, Lee MS, Laidlaw G, Cornelissen IP, Matloubian M, Coughlin SR, McDonald DM, McCune JM. IL-7 production in murine lymphatic endothelial cells and induction in the setting of peripheral lymphopenia. Int Immunol 2013; 25:471-83; PMID:23657000; http://dx.doi. org/10.1093/intimm/dxt012.
39. Andarawewa KL, Paupert J, Pal A, Barcellos-Hoff MH. New rationales for using TGFbeta inhibitors in radiotherapy. Int J Radiat Biol 2007; 83:803-11; PMID:18058368; http://dx.doi. org/10.1080/09553000701711063.
40. Tang J, Nuccie BL, Ritterman I, Liesveld JL, Abboud CN, Ryan DH. TGF-beta down-regulates stromal IL-7 secretion and inhibits proliferation of human B cell precursors. J Immunol 1997; 159:117-25; PMID:9200446.
41. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10:459-66; PMID:19269895; http://dx.doi. org/10.1016/S1470-2045(09)70025-7.
42. Mielke S, Rezvani K, Savani BN, Nunes R, Yong AS, Schindler J, Kurlander R, Ghetie V, Read EJ, Solomon SR, et al. Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease. Blood 2007; 110:1689-97; PMID:17478639; http://dx.doi.org/10.1182/blood-2007-03-079160.